Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy

Journal of Heart and Lung Transplantation

Volumn 26, Issue 8, 2007, Pages 826-833

  Raichlin, Eugenia R ^a   McConnell, Joseph P ^a   Lerman, Amir ^a   Kremers, Walter K ^a   Edwards, Brooks S ^a   Kushwaha, Sudhir S ^a   Clavell, Alfredo L ^a   Rodeheffer, Richard J ^a   Frantz, Robert P ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DEATH; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 34547619046     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.05.008     Document Type: Article

References (36)

1. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 17 (1998) 744-753
2. Gao S.Z., Schroeder J.S., Hunt S., and Stinson E.B. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 62 (1988) 876-881
3. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-879
4. Uretsky B.F., Murali S., Reddy P.S., et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 76 (1987) 827-834
5. Keogh A.M., Valantine H.A., Hunt S.A., et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 11 (1992) 892-901
6. Julius B.K., Attenhofer Jost C.H., Sutsch G., et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation 69 (2000) 847-853
7. Stoica S.C., Cafferty F., Pauriah M., et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 25 (2006) 420-425
8. Valantine H., Rickenbacker P., Kemna M., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 103 (2001) 2144-2152
9. Labarrere C.A., Nelson D.R., and Spear K.L. Non-immunologic vascular failure of the transplanted heart. J Heart Lung Transplant 22 (2003) 236-240
10. Pethig K., Heublein B., Kutschka I., and Haverich A. Systemic inflammatory response in cardiac allograft vasculopathy: highly-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102 suppl (2000) III-233-III-236
11. Hognestad A., Endresen K., Wergeland R., et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 42 (2003) 477-482
12. Laws A., and Reaven G.M. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 231 (1992) 25-30
13. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 (2003) 802-809
14. Bae J.H., Rihal C.S., Edwards B.S., et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 82 (2006) 1108-1111
15. Chaves A.J., Sousa A.G., Mattos L.A., et al. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial. Circulation 109 (2004) 861-866
16. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 38 (2001) 206-213
17. Kemna M.S., Valantine H.A., Hunt S.A., Schroeder J.S., Chen Y.D., and Reaven G.M. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 128 (1994) 68-72
18. Ballantyne C.M., el Masri B., Morrisett J.D., and Torre-Amione G. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol 12 (1997) 153-160
19. Cordero Fort A., Gavira J.J., Alegria-Barrero E., et al. Prevalence of metabolic syndrome in heart transplant patients: role of previous cardiopathy and years since the procedure-the TRACA study. J Heart Lung Transplant 25 (2006) 1192-1198
20. Senechal M., Lemieux I., Beucler I., et al. Features of the metabolic syndrome of "hypertriglyceridemic waist" and transplant coronary artery disease. J Heart Lung Transplant 24 (2005) 819-826
21. Winocour P.H., Durrington P.N., Bhatnagar D., Ishola M., Arrol S., and Mackness M. Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. Arterioscler Thromb 12 (1992) 920-928
22. Yarnell J.W., Sweetnam P.M., Marks V., Teale J.D., and Bolton C.H. Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations?. The Caerphilly prospective study. Br Heart J 71 (1994) 293-296
23. Tchernof A., Lamarche B., Prud'Homme D., et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19 (1996) 629-637
24. Eisenberg M.S., Chen H.J., Warshofsky M.K., et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102 (2000) 2100-2104
25. Katznelson S., Wang X.M., Chia D., et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 17 (1998) 335-340
26. Pearson J.A., Mensah G.A., and Alexander R.W. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and the American Heart Association. Circulation 107 (2003) 499-511
27. Davis S.F., Yeung A.C., Meredith I.T., et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 93 (1996) 457-462
28. Festa A., Hanley A.J., Tracy R.P., D'Agostino Jr. R., and Haffner S.M. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108 (2003) 1822-1830
29. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
30. Pethig K., Heublein B., Wahlers T., Dannenberg O., Oppelt P., and Haverich A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 23 (2004) 61-66
31. Fearon W., Hirohata A., Nakamura M., et al. Discordant changes in epicardial and microvascular coronary physiology after cardiac transplantation: Physiologic Investigation for Transplant Arteriopathy II (PITA II) study. J Heart Lung Transplant 25 (2006) 765-771
32. Eisen H., Tuzcu E., Dorent R., et al., RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. New Engl J Med 349 (2003) 847-858
33. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. J Heart Lung Transplant 24 suppl (2005) S191-S195
34. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 suppl (2004) S187-S193
35. Kushwaha S., Khalpey Z., Frantz R., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 24 (2005) 2129-2136
36. Cantin B., Zhu D., Wen P., et al. Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin. J Heart Lung Transplant 21 (2002) 637-643